Exela Technologies Announces 1 for 20 Reverse Stock Split

Rhea-AI Summary

Exela Technologies, Inc. (NASDAQ: XELA) has announced a 1-for-20 reverse stock split, effective July 25, 2022, at 5:00 p.m. ET. This decision aims to enhance the marketability and liquidity of its shares and ensure compliance with Nasdaq listing requirements. Post-split, approximately 64.8 million shares will be issued and outstanding, trading on a split-adjusted basis starting July 26, 2022. Exela Technologies is recognized as a leader in business process automation and serves over 4,000 customers globally, including more than 60% of the Fortune 100.

Positive

• Reverse stock split may improve stock marketability and liquidity.
• Compliance with Nasdaq listing requirements.

Negative

• Reverse stock split could indicate low share price issues.

IRVING, Texas, July 25, 2022 (GLOBE NEWSWIRE) -- Exela Technologies, Inc. (“Exela” or “Company”) (NASDAQ: XELA), a location-agnostic global business process automation (BPA) leader, announced that its Board of Directors has approved a 1-for-20 reverse stock split of the Company’s common stock, which will be effective at 5:00 p.m. Eastern Time on Monday, July 25, 2022. Exela’s Board of Directors approved the split and determined the 1-for-20 ratio to be appropriate to meet Exela’s goals of improving the marketability and liquidity of its common stock, compliance with Nasdaq listing requirements and allowing the Company’s management team to focus on its business.

As a result of the reverse split, each twenty shares of the Company’s issued and outstanding common stock will be automatically combined and converted into one issued and outstanding share of common stock. The Company’s shares will begin trading on a split-adjusted basis on the Nasdaq Capital Market commencing upon market open on July 26, 2022. Immediately after the reverse split becomes effective, there will be approximately 64.8 million shares of common stock issued and outstanding.   

About Exela Technologies

Exela Technologies is a business process automation (BPA) leader, leveraging a global footprint and proprietary technology to provide digital transformation solutions enhancing quality, productivity, and end-user experience. With decades of experience operating mission-critical processes, Exela serves a growing roster of more than 4,000 customers throughout 50 countries, including over 60% of the Fortune^® 100. Utilizing foundational technologies spanning information management, workflow automation, and integrated communications, Exela’s software and services include multi-industry, departmental solution suites addressing finance and accounting, human capital management, and legal management, as well as industry-specific solutions for banking, healthcare, insurance, and the public sector. Through cloud-enabled platforms, built on a configurable stack of automation modules, and approximately 17,000 employees operating in 23 countries, Exela rapidly deploys integrated technology and operations as an end-to-end digital journey partner.

For more Exela news, commentary, and industry perspectives, visit: https://investors.exelatech.com/

And please follow us on social:

Twitter: https://twitter.com/exelatech

LinkedIn: https://www.linkedin.com/company/exela-technologies

Facebook: https://www.facebook.com/exelatechnologies/

Instagram: https://www.instagram.com/exelatechnologies

The information posted on the Company's website and/or via its social media accounts may be deemed material to investors. Accordingly, investors, media and others interested in the Company should monitor the Company's website and its social media accounts in addition to the Company's press releases, SEC filings and public conference calls and webcasts.

Forward-Looking Statements

Certain statements included in this press release are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as "may", "should", "would", "plan", "intend", "anticipate", "believe", "estimate", "predict", "potential", "seem", "seek", "continue", "future", "will", "expect", "outlook" or other similar words, phrases or expressions. These forward-looking statements include statements regarding our industry, future events, estimated or anticipated future results and benefits, future opportunities for Exela, and other statements that are not historical facts. These statements are based on the current expectations of Exela management and are not predictions of actual performance. These statements are subject to a number of risks and uncertainties, including without limitation those discussed under the heading "Risk Factors" in Exela's Annual Report and other securities filings. In addition, forward-looking statements provide Exela's expectations, plans or forecasts of future events and views as of the date of this communication. Exela anticipates that subsequent events and developments will cause Exela's assessments to change. These forward-looking statements should not be relied upon as representing Exela's assessments as of any date subsequent to the date of this press release.

Investor and/or Media Contacts:

Vincent Kondaveeti
E: vincent.kondaveeti@exelatech.com

Mary Beth Benjamin
E: IR@exelatech.com

FAQ

What is the effective date of Exela Technologies' reverse stock split?

The reverse stock split is effective on July 25, 2022.

What will be the new share structure for Exela after the reverse stock split?

After the reverse split, there will be approximately 64.8 million shares issued and outstanding.

Why did Exela Technologies decide on a 1-for-20 reverse stock split?

The reverse split aims to improve marketability, liquidity, and compliance with Nasdaq listing requirements.

When will Exela's shares start trading on a split-adjusted basis?

Exela's shares will begin trading on a split-adjusted basis on July 26, 2022.

What is the stock symbol for Exela Technologies?

Exela Technologies trades under the symbols XELA, XELAW, and XELAP.